⌕
Scribe Therapeutics · SCTX · Nasdaq
Tenet — · insufficient data
Compare
$15.37−6.05%At close
$15.37−0.99 (−6.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Scribe Therapeutics (SCTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 12, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400  Continued enrollment in first-in-human Phase 1 clinical …

● GlobeNewsWireNov 5, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences

ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technol…

● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026

Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe's lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will reveal…

● Seeking AlphaOct 15, 2026 · 09:06 ET
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst

Scribe Therapeutics is initiated with a buy rating, targeting the in-vivo gene therapy market for cardiometabolic diseases with lead asset STX-1150. STX-1150 aims to provide durable, reversible PCSK9 silencing for choles…

● Defense WorldSep 28, 2026 · 04:15 ET
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts

Scribe Therapeutics Inc. (NASDAQ: SCTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five research firms that are covering the company, MarketBeat Ratings reports. One investment analy…

● GlobeNewsWireSep 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering witho…

● GlobeNewsWireSep 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Scribe Therapeutics to Participate in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed t…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just SCTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.